rtmark
LearnBonds.com

Johnson & Johnson (NYSE:JNJ) Shows Off Mixed Third Quarter Results

Johnson & Johnson (JNJ)

Johnson & Johnson , right before the market opened on Tuesday 13, October, showed off its earnings numbers for the three months through September. Earnings for the quarter came in at $1.49. The firm showed sales totaling $17.1B for the three months.

Johnson & Johnson (JNJ)

In the run up to the release of today’s results, analysts following the firm were looking for earnings per share of $1.44 from Johnson & Johnson for the quarter. Sales for the period were forecast to come in at $17.41 by consensus.

Johnson & Johnson results by comparison

The same three months of 2014 saw Johnson & Johnson earn $1.66 on sales that came to $18,45B. In the last twelve months shares in the firm have lost 5.9% of their value in the last twelve month. In the three months leading into the release of these results the firm lost 4.54%

Johnson & Johnson

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices.

Analysts look at Johnson & Johnson

Johnson & Johnson is expected to make a profit of $1.49 per share for the twelve months of its current fiscal year. Full sales for the year are forecast to come in at $70.57B.

In the last full fiscal year, Johnson & Johnson gain $1.49 Annual EPS]. Sales came in at $17.1B

Of the 19 analysts covering the firm for Wall Street, 5 analysts said that clients should Buy shares in the firm, 4 analysts rated the shares at Overweight, while 9 analysts said that holding the shares was the best option going forward.

1 analyst said that clients should keep the shares Underweight in their portfolios, while none said that their best idea was to Sell the shares ahead of the release of this earnings report.

 

All trading carries risk. Views expressed are those of the writers only. Past performance is no guarantee of future results. The opinions expressed in this Site do not constitute investment advice and independent financial advice should be sought where appropriate. This website is free for you to use but we may receive commission from the companies we feature on this site.
Avatar

Victor Alagbe is a seasoned business and finance writer with a specialty in writing about how to invest for the long-term in healthcare, pharmacology, energy and tech stocks. His long-term focus is on stocks that provide a nice mix of growth and income. For the short term, he passionately writes about trading stock options for the excitement and leverage that stock options offer.

X

Leading Social Trading Platform with 0% Commission

Leading Social Trading Platform with 0% Commission

Leading Social Trading Platform with 0% Commission

TRADE WITH ETORO

75% of investors lose money when trading CFDs.

Leading Social Trading Platform with 0% Commission
TRADE WITH ETORO

75% of investors lose money when trading CFDs.

HTML Snippets Powered By : XYZScripts.com